Continuing the Suspension of Duty-Free De Minimis Treatment for All Countries
The suspension of duty-free de minimis treatment for all countries is continued, meaning small-value shipments (under $800) are no longer exempt from customs duties and taxes. This affects importers of pharmaceutical goods, including raw materials, APIs, and finished products, increasing costs and administrative burden.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on July 27, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated High urgency. Branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, compounding outsourcing (503B) facilities that import goods via de minimis shipments. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Immediately; the suspension is already in effect as of the publication date.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
The temporary suspension of duty-free de minimis treatment (Section 321) for all countries is continued, so all imported shipments under $800 are now subject to duties, taxes, and formal entry requirements.
Who it affects
Branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, compounding outsourcing (503B) facilities that import goods via de minimis shipments.
What you must do
Review import processes to ensure all shipments, including low-value ones, are properly declared and duties paid. Update customs brokers and logistics partners on new requirements.
Deadline
Immediately; the suspension is already in effect as of the publication date.
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- FDA Issues Draft Guidance to Cut Unnecessary Animal Testing for Cancer Drugs
- FDA Issues Draft Guidance to Help Accelerate Cell and Gene Therapies for Patients
- FDA Expands Sunscreen Options for the First Time in 20 Years
- FDA Issues Emergency Use Authorization for Generic Over-the-Counter Drug to Treat New World Screwworm in Dogs and Cats
- FDA Broadens Access to Over-the-Counter Naloxone Nasal Spray for Opioid Overdose